ZA200210277B - Melanocortin receptor ligands. - Google Patents
Melanocortin receptor ligands. Download PDFInfo
- Publication number
- ZA200210277B ZA200210277B ZA200210277A ZA200210277A ZA200210277B ZA 200210277 B ZA200210277 B ZA 200210277B ZA 200210277 A ZA200210277 A ZA 200210277A ZA 200210277 A ZA200210277 A ZA 200210277A ZA 200210277 B ZA200210277 B ZA 200210277B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- benzyl
- independently
- hydrogen
- ethyl
- Prior art date
Links
- 102000004378 Melanocortin Receptors Human genes 0.000 title claims description 6
- 108090000950 Melanocortin Receptors Proteins 0.000 title claims description 6
- 239000003446 ligand Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 107
- 150000001875 compounds Chemical class 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 54
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- -1 hydroxy, nitro, amino, cyano, phenyl Chemical group 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 230000002265 prevention Effects 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 19
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 8
- 235000019789 appetite Nutrition 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 6
- 235000012631 food intake Nutrition 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 208000007976 Ketosis Diseases 0.000 claims description 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 239000000674 adrenergic antagonist Substances 0.000 claims description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000003529 anticholesteremic agent Substances 0.000 claims description 2
- 229940127226 anticholesterol agent Drugs 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 230000004634 feeding behavior Effects 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000004140 ketosis Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 230000037323 metabolic rate Effects 0.000 claims description 2
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims description 2
- 150000004713 phosphodiesters Chemical class 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- OOAQRHNPIWYHIL-GCJKJVERSA-N (8aS)-7-[(2R)-2-amino-3-(4-chlorophenyl)propanoyl]-8a-(pyridin-3-ylmethyl)-2-(2,2,2-trifluoroethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1,3-dione Chemical compound C([C@@H](N)C(=O)N1C[C@@]2(CC=3C=NC=CC=3)C(=O)N(CC(F)(F)F)C(=O)N2CC1)C1=CC=C(Cl)C=C1 OOAQRHNPIWYHIL-GCJKJVERSA-N 0.000 claims 1
- MIVKGLRFZYNBJK-LCQOSCCDSA-N 7-[(2R)-2-amino-3-(4-chlorophenyl)propanoyl]-8a-[(4-fluorophenyl)methyl]-1,5,6,8-tetrahydro-[1,3]oxazolo[3,4-a]pyrazin-3-one Chemical compound C([C@@H](N)C(=O)N1CC2(CC=3C=CC(F)=CC=3)COC(=O)N2CC1)C1=CC=C(Cl)C=C1 MIVKGLRFZYNBJK-LCQOSCCDSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 101150004219 MCR1 gene Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000008064 Corticotropin Receptors Human genes 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical group CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21461600P | 2000-06-28 | 2000-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200210277B true ZA200210277B (en) | 2003-12-19 |
Family
ID=22799775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200210277A ZA200210277B (en) | 2000-06-28 | 2002-12-19 | Melanocortin receptor ligands. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20020072604A1 (no) |
| EP (1) | EP1294719A1 (no) |
| JP (1) | JP2004501917A (no) |
| KR (1) | KR20030017571A (no) |
| CN (1) | CN1440406A (no) |
| AP (1) | AP2001002196A0 (no) |
| AR (1) | AR030301A1 (no) |
| AU (1) | AU2001260548A1 (no) |
| BG (1) | BG107268A (no) |
| BR (1) | BR0111567A (no) |
| CA (1) | CA2412563A1 (no) |
| EA (1) | EA200201119A1 (no) |
| EC (1) | ECSP024404A (no) |
| IL (1) | IL152781A0 (no) |
| IS (1) | IS6617A (no) |
| MA (1) | MA26920A1 (no) |
| MX (1) | MXPA03000063A (no) |
| NO (1) | NO20026280L (no) |
| OA (1) | OA12296A (no) |
| PA (1) | PA8521501A1 (no) |
| PE (1) | PE20020208A1 (no) |
| PL (1) | PL360855A1 (no) |
| TN (1) | TNSN01097A1 (no) |
| UY (1) | UY26804A1 (no) |
| WO (1) | WO2002000654A1 (no) |
| ZA (1) | ZA200210277B (no) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091752A1 (en) * | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
| CA2438272A1 (en) | 2001-03-02 | 2002-10-10 | John Macor | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| JP2005519876A (ja) | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| TW200504033A (en) | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| WO2004069798A1 (ja) | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| EP1661898A4 (en) * | 2003-08-29 | 2009-04-15 | Takeda Pharmaceutical | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| KR20100118615A (ko) * | 2004-04-08 | 2010-11-05 | 아스테라스 세이야쿠 가부시키가이샤 | 화합물 ｗｓ727713 |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| EP2236151B1 (en) * | 2005-07-08 | 2012-05-23 | Ipsen Pharma | Melanocortin receptor ligands |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| DE602007004615D1 (de) | 2006-06-30 | 2010-03-18 | Boehringer Ingelheim Pharma | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen |
| JPWO2008007664A1 (ja) | 2006-07-11 | 2009-12-10 | 武田薬品工業株式会社 | 二環性複素環化合物およびその用途 |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| CN101505736A (zh) | 2006-08-25 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| CA2689016C (en) | 2007-05-25 | 2014-08-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
| PE20091188A1 (es) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen |
| EP2224929B1 (en) | 2007-12-17 | 2016-05-04 | Janssen Pharmaceutica, N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3768799A (en) * | 1998-04-28 | 1999-11-16 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| EP1085869A4 (en) * | 1998-06-11 | 2001-10-04 | Merck & Co Inc | SPIRO PIPERID DERIVATIVES AS MELANOCORTIN RECEPTORAGONISTS |
| JP2003505435A (ja) * | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
-
2001
- 2001-05-31 MX MXPA03000063A patent/MXPA03000063A/es unknown
- 2001-05-31 CA CA002412563A patent/CA2412563A1/en not_active Abandoned
- 2001-05-31 OA OA1200200389A patent/OA12296A/en unknown
- 2001-05-31 KR KR1020027017822A patent/KR20030017571A/ko not_active Application Discontinuation
- 2001-05-31 AU AU2001260548A patent/AU2001260548A1/en not_active Abandoned
- 2001-05-31 AP APAP/P/2001/002196A patent/AP2001002196A0/en unknown
- 2001-05-31 JP JP2002505778A patent/JP2004501917A/ja not_active Withdrawn
- 2001-05-31 CN CN01812163A patent/CN1440406A/zh active Pending
- 2001-05-31 PL PL36085501A patent/PL360855A1/xx not_active Application Discontinuation
- 2001-05-31 IL IL15278101A patent/IL152781A0/xx unknown
- 2001-05-31 EP EP01934254A patent/EP1294719A1/en not_active Withdrawn
- 2001-05-31 WO PCT/IB2001/000995 patent/WO2002000654A1/en not_active Application Discontinuation
- 2001-05-31 BR BR0111567-7A patent/BR0111567A/pt not_active IP Right Cessation
- 2001-05-31 EA EA200201119A patent/EA200201119A1/ru unknown
- 2001-06-25 US US09/891,026 patent/US20020072604A1/en not_active Abandoned
- 2001-06-26 PE PE2001000626A patent/PE20020208A1/es not_active Application Discontinuation
- 2001-06-26 AR ARP010103037A patent/AR030301A1/es unknown
- 2001-06-27 TN TNTNSN01097A patent/TNSN01097A1/fr unknown
- 2001-06-27 UY UY26804A patent/UY26804A1/es not_active Application Discontinuation
- 2001-06-28 PA PA20018521501A patent/PA8521501A1/es unknown
-
2002
- 2002-11-12 BG BG107268A patent/BG107268A/xx unknown
- 2002-11-14 IS IS6617A patent/IS6617A/is unknown
- 2002-12-19 ZA ZA200210277A patent/ZA200210277B/en unknown
- 2002-12-24 MA MA26976A patent/MA26920A1/fr unknown
- 2002-12-26 EC EC2002004404A patent/ECSP024404A/es unknown
- 2002-12-30 NO NO20026280A patent/NO20026280L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP024404A (es) | 2003-02-06 |
| PA8521501A1 (es) | 2002-10-24 |
| UY26804A1 (es) | 2002-01-31 |
| AU2001260548A1 (en) | 2002-01-08 |
| NO20026280D0 (no) | 2002-12-30 |
| AP2001002196A0 (en) | 2002-12-21 |
| MA26920A1 (fr) | 2004-12-20 |
| BG107268A (en) | 2003-06-30 |
| MXPA03000063A (es) | 2003-09-25 |
| EP1294719A1 (en) | 2003-03-26 |
| JP2004501917A (ja) | 2004-01-22 |
| CN1440406A (zh) | 2003-09-03 |
| US20020072604A1 (en) | 2002-06-13 |
| KR20030017571A (ko) | 2003-03-03 |
| CA2412563A1 (en) | 2002-01-03 |
| IL152781A0 (en) | 2003-06-24 |
| PE20020208A1 (es) | 2002-03-13 |
| IS6617A (is) | 2002-11-14 |
| PL360855A1 (en) | 2004-09-20 |
| WO2002000654A1 (en) | 2002-01-03 |
| TNSN01097A1 (fr) | 2005-11-10 |
| BR0111567A (pt) | 2003-05-06 |
| OA12296A (en) | 2006-05-12 |
| EA200201119A1 (ru) | 2003-06-26 |
| AR030301A1 (es) | 2003-08-20 |
| NO20026280L (no) | 2002-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200210277B (en) | Melanocortin receptor ligands. | |
| CA2860951C (en) | Imidazopyrrolidinone compounds | |
| CN111491934B (zh) | 作为激酶抑制剂的氨基-氟哌啶衍生物 | |
| ES2285715T3 (es) | Secretagodos de la hormona del crecimiento. | |
| ES2377975T3 (es) | Composición medicinal que comprende un inhibidor de la HMG-CoA reductasa y un derivado de aminoalcohol como inmunodepresor | |
| US20190315756A1 (en) | Brk inhibitory compound | |
| CA2395593A1 (en) | Azaindoles | |
| US20090209573A1 (en) | Compounds and compositions as hedgehog pathway modulators | |
| ES2586231T3 (es) | Inhibidores de glutaminil ciclasa | |
| JP2005508311A (ja) | ｏ−フェニレンジアミンのＮ−モノアシル化誘導体、その六員複素環式アナログ、及び薬剤としてのそれらの使用 | |
| JP2009502920A5 (no) | ||
| JP2003500404A5 (no) | ||
| KR20130029368A (ko) | Ｍｇｌｕｒ4 알로스테릭 강화제로서 피라졸로피리딘, 피라졸로피라진, 피라졸로피리미딘, 피라졸로티오펜 및 피라졸로티아졸 화합물, 조성물, 및 신경 기능이상을 치료하는 방법 | |
| EP3560926B1 (en) | 6-amino-7,9-dihydro-8h-purin-8-one compounds as brk inhibitors | |
| JP7101688B2 (ja) | ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ | |
| CA2787323C (en) | Therapeutic or prophylactic agent for biliary tract diseases | |
| JP2019529521A (ja) | Ｓｇｃアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ | |
| JP2022501344A (ja) | 新規キナゾリンｅｇｆｒ阻害剤 | |
| EA002089B1 (ru) | Способ лечения резистентности к инсулину средствами, стимулирующими секрецию гормона роста | |
| JP2018520151A (ja) | 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用 | |
| JP2016132649A (ja) | 新規イミダゾピリジン誘導体およびその医薬用途 | |
| NZ230098A (en) | Compositions containing substituted 2,3-dihydroimidazo-(2,1-a) isoquinolines | |
| RU2012141061A (ru) | Агонист рецептора грелина для лечения кахексии | |
| AU2012217903A1 (en) | Peripherially acting mu opioid antagonists | |
| JPH10502657A (ja) | ヘテロ環縮合モルヒノイド誘導体 |